Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
Wang Y, Chackalamannil S, Hu Z, Boyle CD, Lankin CM, Xia Y, Xu R, Asberom T, Pissarnitski D, Stamford AW, Greenlee WJ, Skell J, Kurowski S, Vemulapalli S, Palamanda J, Chintala M, Wu P, Myers J, Wang P. Wang Y, et al. Among authors: palamanda j. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3149-52. doi: 10.1016/s0960-894x(02)00646-7. Bioorg Med Chem Lett. 2002. PMID: 12372521
SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
Pissarnitski DA, Asberom T, Boyle CD, Chackalamannil S, Chintala M, Clader JW, Greenlee WJ, Hu Y, Kurowski S, Myers J, Palamanda J, Stamford AW, Vemulapalli S, Wang Y, Wang P, Wu P, Xu R. Pissarnitski DA, et al. Among authors: palamanda j. Bioorg Med Chem Lett. 2004 Mar 8;14(5):1291-4. doi: 10.1016/j.bmcl.2003.12.027. Bioorg Med Chem Lett. 2004. PMID: 14980684
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD, Xu R, Asberom T, Chackalamannil S, Clader JW, Greenlee WJ, Guzik H, Hu Y, Hu Z, Lankin CM, Pissarnitski DA, Stamford AW, Wang Y, Skell J, Kurowski S, Vemulapalli S, Palamanda J, Chintala M, Wu P, Myers J, Wang P. Boyle CD, et al. Among authors: palamanda j. Bioorg Med Chem Lett. 2005 May 2;15(9):2365-9. doi: 10.1016/j.bmcl.2005.02.083. Bioorg Med Chem Lett. 2005. PMID: 15837326
Metabolism-based identification of a potent thrombin receptor antagonist.
Clasby MC, Chackalamannil S, Czarniecki M, Doller D, Eagen K, Greenlee W, Kao G, Lin Y, Tsai H, Xia Y, Ahn HS, Agans-Fantuzzi J, Boykow G, Chintala M, Foster C, Smith-Torhan A, Alton K, Bryant M, Hsieh Y, Lau J, Palamanda J. Clasby MC, et al. Among authors: palamanda j. J Med Chem. 2007 Jan 11;50(1):129-38. doi: 10.1021/jm061043e. J Med Chem. 2007. PMID: 17201416
Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.
Chelliah MV, Chackalamannil S, Xia Y, Eagen K, Clasby MC, Gao X, Greenlee W, Ahn HS, Agans-Fantuzzi J, Boykow G, Hsieh Y, Bryant M, Palamanda J, Chan TM, Hesk D, Chintala M. Chelliah MV, et al. Among authors: palamanda j. J Med Chem. 2007 Oct 18;50(21):5147-60. doi: 10.1021/jm070704k. Epub 2007 Sep 14. J Med Chem. 2007. PMID: 17854166
Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
Mandal M, Mitra K, Grotz D, Lin X, Palamanda J, Kumari P, Buevich A, Caldwell JP, Chen X, Cox K, Favreau L, Hyde L, Kennedy ME, Kuvelkar R, Liu X, Mazzola RD, Parker E, Rindgen D, Sherer E, Wang H, Zhu Z, Stamford AW, Cumming JN. Mandal M, et al. Among authors: palamanda j. J Med Chem. 2018 Dec 13;61(23):10700-10708. doi: 10.1021/acs.jmedchem.8b01326. Epub 2018 Nov 15. J Med Chem. 2018. PMID: 30388368
37 results